Guangdong Hybribio Biotech Co.,Ltd. (SHE:300639)
5.10
+0.05 (0.99%)
Apr 30, 2025, 3:04 PM CST
SHE:300639 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 815.53 | 1,075 | 5,519 | 2,647 | 1,340 | Upgrade
|
Other Revenue | - | 29.75 | 78.35 | 26.43 | 14.13 | Upgrade
|
Revenue | 815.53 | 1,104 | 5,597 | 2,673 | 1,354 | Upgrade
|
Revenue Growth (YoY) | -26.16% | -80.27% | 109.39% | 97.34% | 85.70% | Upgrade
|
Cost of Revenue | 426.72 | 442.1 | 1,807 | 865.5 | 361.09 | Upgrade
|
Gross Profit | 388.8 | 662.35 | 3,790 | 1,808 | 993.4 | Upgrade
|
Selling, General & Admin | 482 | 532.48 | 847.68 | 581.7 | 445.73 | Upgrade
|
Research & Development | 85.64 | 136.32 | 247.28 | 115.29 | 71.62 | Upgrade
|
Other Operating Expenses | 5.1 | 9.93 | 21.3 | 12.88 | 7.33 | Upgrade
|
Operating Expenses | 572.74 | 667.97 | 1,367 | 761.63 | 543.83 | Upgrade
|
Operating Income | -183.94 | -5.62 | 2,424 | 1,046 | 449.57 | Upgrade
|
Interest Expense | - | -4.94 | -8.18 | -7.4 | -0.8 | Upgrade
|
Interest & Investment Income | 5.15 | 47.45 | 36.4 | 24.42 | 9.86 | Upgrade
|
Currency Exchange Gain (Loss) | - | -15.89 | -2.36 | 0.86 | -0.31 | Upgrade
|
Other Non Operating Income (Expenses) | -620.24 | -1.55 | -2.29 | -1.21 | -1.13 | Upgrade
|
EBT Excluding Unusual Items | -799.02 | 19.44 | 2,447 | 1,063 | 457.19 | Upgrade
|
Gain (Loss) on Sale of Investments | 4.05 | -0 | 0.04 | 0.14 | - | Upgrade
|
Gain (Loss) on Sale of Assets | -0.25 | 7.06 | 4.34 | 2.34 | 5.06 | Upgrade
|
Asset Writedown | -37.75 | 1.56 | -291.74 | -6.42 | -0.59 | Upgrade
|
Other Unusual Items | - | 8.76 | -31.96 | -1.44 | 2.31 | Upgrade
|
Pretax Income | -832.97 | 36.82 | 2,128 | 1,057 | 463.98 | Upgrade
|
Income Tax Expense | 117.38 | -31.7 | 326.06 | 172.24 | 69.32 | Upgrade
|
Earnings From Continuing Operations | -950.35 | 68.51 | 1,802 | 884.94 | 394.66 | Upgrade
|
Minority Interest in Earnings | 295.47 | 71.96 | -75.81 | -32.78 | -31.99 | Upgrade
|
Net Income | -654.88 | 140.47 | 1,726 | 852.16 | 362.66 | Upgrade
|
Net Income to Common | -654.88 | 140.47 | 1,726 | 852.16 | 362.66 | Upgrade
|
Net Income Growth | - | -91.86% | 102.54% | 134.97% | 146.22% | Upgrade
|
Shares Outstanding (Basic) | 642 | 562 | 659 | 659 | 614 | Upgrade
|
Shares Outstanding (Diluted) | 642 | 562 | 659 | 659 | 614 | Upgrade
|
Shares Change (YoY) | 14.27% | -14.71% | -0.02% | 7.39% | 3.55% | Upgrade
|
EPS (Basic) | -1.02 | 0.25 | 2.62 | 1.29 | 0.59 | Upgrade
|
EPS (Diluted) | -1.02 | 0.25 | 2.62 | 1.29 | 0.59 | Upgrade
|
EPS Growth | - | -90.46% | 102.58% | 118.80% | 137.77% | Upgrade
|
Free Cash Flow | -69.55 | -65.72 | 574.85 | -9.73 | 24.18 | Upgrade
|
Free Cash Flow Per Share | -0.11 | -0.12 | 0.87 | -0.01 | 0.04 | Upgrade
|
Dividend Per Share | - | 0.065 | 0.233 | 0.155 | 0.089 | Upgrade
|
Dividend Growth | - | -72.14% | 50.03% | 74.13% | 25.77% | Upgrade
|
Gross Margin | 47.67% | 59.97% | 67.72% | 67.62% | 73.34% | Upgrade
|
Operating Margin | -22.55% | -0.51% | 43.30% | 39.13% | 33.19% | Upgrade
|
Profit Margin | -80.30% | 12.72% | 30.84% | 31.88% | 26.77% | Upgrade
|
Free Cash Flow Margin | -8.53% | -5.95% | 10.27% | -0.36% | 1.79% | Upgrade
|
EBITDA | -23.43 | 156.27 | 2,591 | 1,127 | 499.61 | Upgrade
|
EBITDA Margin | -2.87% | 14.15% | 46.29% | 42.17% | 36.89% | Upgrade
|
D&A For EBITDA | 160.51 | 161.89 | 167.29 | 81.33 | 50.04 | Upgrade
|
EBIT | -183.94 | -5.62 | 2,424 | 1,046 | 449.57 | Upgrade
|
EBIT Margin | -22.55% | -0.51% | 43.30% | 39.13% | 33.19% | Upgrade
|
Effective Tax Rate | - | - | 15.32% | 16.29% | 14.94% | Upgrade
|
Revenue as Reported | - | 1,104 | 5,597 | 2,673 | 1,354 | Upgrade
|
Advertising Expenses | - | 24.2 | 36.3 | 29.35 | 20.11 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.